Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report

Huang,Shigao; Dang,Yazheng; Li,Fujun; Wei,Wei; Ma,Yuxin; Qiao,Song; Wang,Qianyun

doi:10.3892/ol.2014.2820

Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report

Authors:
- Shigao Huang
- Yazheng Dang
- Fujun Li
- Wei Wei
- Yuxin Ma
- Song Qiao
- Qianyun Wang
View Affiliations

Affiliations: Department of Oncology, Chinese People's Liberation Army 323 Hospital, Xi'an, Shaanxi 710054, P.R. China
Published online on: December 22, 2014 https://doi.org/10.3892/ol.2014.2820
Pages: 1239-1243

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study presents the case of a 68‑year‑old female patient who received biological intensity‑modulated radiotherapy (BIMRT) and neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer. The International Federation of Gynecology and Obstetrics disease stage was Ⅲc. In addition, the patient presented with urination and defecation difficulties. The result of tumor marker detection showed a carcinoembryonic antigen level of 348.2ng/ml, a cancer antigen 125 level of 2,091 U/ml and a cancer antigen 19‑9 level of 113 U/ml. Computed tomography (CT) indicated and ovarian cystic or solid package, enlargement of multiple abdominal and retroperitoneal lymph nodes and abdominal cavity effusion. Positron emission tomography/CT indicated multiple internal organ metastases. The center of the ovarian cystic or solid package was considered to be a malignant tumor. A large amount of ascites were detected, as well as abdominal and retroperitoneal lymph node metastasis. The patient was treated with BIMRT at a total dose of 48 Gy, administered as a single 4.0‑Gy dose 12 times. In addition, 100 mg cisplatin was administered as a peritoneal perfusion, followed by two cycles of 180 mg Taxol and 100 mg cisplatin. Furthermore, the enlargement of the lymph nodes was reduced and the tumor in the region of the ovary had decreased in size by 90%. The ascites had disappeared and the abdominal pain was greatly improved. At the time of writing this manuscript, the patient was well and without relapse. Therefore, modern radiotherapy techniques, such as BIMRT, may be considered as a beneficial treatment option for ovarian cancer patients with multiple peritoneal metastases in whom surgery is not suitable.

View Figures

View References

1	Bristow RE, Duska LR, Lambrou NC, et al: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 89:1532–1540. 2000. View Article : Google Scholar : PubMed/NCBI
2	Parazzini F, Valsecchi G, Bolis G, et al: Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival. Gynecol Oncol. 74:7–11. 1999. View Article : Google Scholar : PubMed/NCBI
3	Pereira A, Magrina JF, Rey V, Cortes M and Magtibay PM: Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol. 105:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
4	Du Bois A and Pfisterer J: Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer. 15(Suppl 1): 42–50. 2005. View Article : Google Scholar : PubMed/NCBI
5	Winter WE III, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 25:3621–3627. 2007. View Article : Google Scholar : PubMed/NCBI
6	Onda T: Neoadjuvant chemotherapy for ovarian cancer. Gan To Kagaku Ryoho. 39:882–886. 2012.PubMed/NCBI
7	Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 18:106–115. 2000.PubMed/NCBI
8	Mouratidou D, Gennatas C, Michalaki V, et al: A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res. 27:681–685. 2007.PubMed/NCBI
9	Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 4:1001–1007. 2001.
10	Kumar A, Gilks CB, Mar C, Santos J and Tinker AV: Patterns of spread of clear cell ovarian cancer: Case report and case series. Gynecol Oncol Rep. 6:25–27. 2013. View Article : Google Scholar
11	Petit T, Velten M, d’Hombres A, et al: Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecologic Oncology. 104:104–108. 2007. View Article : Google Scholar
12	Marsden DE, Friedlander M and Hacker NF: Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol. 19:11–19. 2000. View Article : Google Scholar : PubMed/NCBI
13	Risum S, Høgdall C, Loft A, et al: The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol Oncol. 105:145–149. 2007. View Article : Google Scholar : PubMed/NCBI
14	FIGO-International Federation of Gynaecologists and Obstetricians Cancer Committee. Annual Report on the Results of Treatment in Gynaecological Cancer. FIGO; Stockholm: 1979
15	Ozols RF, Bundy BN, Greer BE, et al: Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
16	Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
17	Gadducci A, Cosio S, Conte PF and Genazzani AR: Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Critl Rev Oncol Hematol. 55:153–166. 2005. View Article : Google Scholar
18	Morrison J, Haldar K, Kehoe S and Lawrie TA: Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 8:CD0053432012.PubMed/NCBI
19	Onda T and Yoshikawa H: Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther. 11:1053–1067. 2011. View Article : Google Scholar : PubMed/NCBI
20	Lambert HE, Gregory WM, Nelstrop AE and Rustin GJ: Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: Life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 14:772–778. 2004. View Article : Google Scholar : PubMed/NCBI
21	Rochet N, Sterzing F, Jensen AD, Dinkel J, Herfarth KK, Schubert K, et al: Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys. 76:1382–1389. 2010. View Article : Google Scholar